{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:43:10Z","timestamp":1792604590260,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.phrs.2020.105332","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T20:12:45Z","timestamp":1606767165000},"page":"105332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data"],"prefix":"10.1016","volume":"163","author":[{"given":"Livia","family":"Lenzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Bonchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105332_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","article-title":"Primary aldosteronism: cardiovascular, renal and metabolic implications","volume":"19","author":"Rossi","year":"2008","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.105332_bib0015","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2020.105332_bib0020","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2020.105332_bib0025","article-title":"Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: a proof-of-concept study","author":"Torresan","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2020.105332_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0035","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","article-title":"Primary aldosteronism: JACC state-of-the-art review","volume":"74","author":"Rossi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2020.105332_bib0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","article-title":"Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study","volume":"55","author":"Gaddam","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2020.105332_bib0045","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Pr","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2020.105332_bib0050","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","article-title":"2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology ESH\/ESCTask Force for the Management of Arterial Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2020.105332_bib0055","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.105332_bib0060","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2011-2830","article-title":"The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism","volume":"97","author":"Rossi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.105332_bib0065","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","article-title":"Adverse effects of mineralocorticoid receptor antagonist administration","volume":"24","author":"Kallistratos","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2020.105332_bib0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2020.105332_bib0075","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/acs.jmedchem.5b00407","article-title":"Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors","volume":"58","author":"Papillon","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105332_bib0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension."},{"key":"10.1016\/j.phrs.2020.105332_bib0085","doi-asserted-by":"crossref","DOI":"10.1177\/1470320317717883","article-title":"LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase","volume":"18","author":"Sloan-Lancaster","year":"2017","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.phrs.2020.105332_bib0090","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.bmcl.2017.03.034","article-title":"4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures","volume":"27","author":"Meguro","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105332_bib0095","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1021\/acs.jmedchem.5b01545","article-title":"Discovery of N -[5-(6-Chloro-3-cyano-1-methyl-1 H -indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects","volume":"58","author":"Papillon","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105332_bib0100","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/acs.jmedchem.8b00328","article-title":"Discovery of novel pyrazole-based selective aldosterone synthase (CYP11B2) inhibitors: a new template to coordinate the heme-iron motif of CYP11B2","volume":"61","author":"Sakakibara","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105332_bib0105","first-page":"982","article-title":"In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors","volume":"39","author":"Bergstr\u00f6m","year":"1998","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.116.236463","article-title":"Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates","volume":"359","author":"Weldon","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2020.105332_bib0115","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.bmcl.2017.04.021","article-title":"Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension","volume":"27","author":"Hoyt","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105332_bib0120","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/acsmedchemlett.9b00152","article-title":"Development of highly selective pyrimidine-based aldosterone synthase (CYP11B2) inhibitors","volume":"10","author":"Sparks","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105332_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.04.007","article-title":"Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11\u03b2-hydroxylase and aldosterone synthase","volume":"192","author":"Akram","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.phrs.2020.105332_bib0130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","article-title":"The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes","volume":"428","author":"Van Zundert","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2020.105332_bib0135","first-page":"1","article-title":"Modelling dynamics in protein crystal structures by ensemble refinement","volume":"2012","author":"Burnley","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2020.105332_bib0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of macromolecular assemblies from crystalline state","volume":"372","author":"Krissinel","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2020.105332_bib0145","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-69-4-896","article-title":"The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro","volume":"69","author":"Lamberts","year":"1989","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.105332_bib0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ab.2009.07.025","article-title":"Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors","volume":"394","author":"LaSala","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.phrs.2020.105332_bib0155","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2020.105332_bib0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10822-007-9128-9","article-title":"Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics","volume":"21","author":"Roumen","year":"2007","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2020.105332_bib0165","first-page":"275","article-title":"PET imaging of adrenal cortical tumors with the 11 \u03b2-hydroxylase tracer 11C-metomidate","volume":"41","author":"Bergstr\u00f6m","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0170","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1095-0397(99)00099-0","article-title":"PET with [11C]-metomidate for the visualization of adrenocortical tumors and discrimination from other lesions","volume":"2","author":"Bergstr\u00f6m","year":"1999","journal-title":"Clin. Positron Imaging"},{"key":"10.1016\/j.phrs.2020.105332_bib0175","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/jc.2005-2273","article-title":"[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings","volume":"91","author":"Hennings","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.105332_bib0180","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.105332_bib0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00259-002-1025-9","article-title":"11C-metomidate PET imaging of adrenocortical cancer","volume":"30","author":"Khan","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.phrs.2020.105332_bib0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nucmedbio.2018.11.002","article-title":"Development of [18 F]FAMTO: a novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands","volume":"68\u201369","author":"Bongarzone","year":"2019","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.phrs.2020.105332_bib0195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fchem.2017.00104","article-title":"Pharmacophore modeling and in Silico\/in vitro screening for human cytochrome P450 11B1 and cytochrome P450 11B2 inhibitors","volume":"5","author":"Akram","year":"2017","journal-title":"Front. Chem."},{"key":"10.1016\/j.phrs.2020.105332_bib0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejphar.2016.11.049","article-title":"A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure","volume":"795","author":"Furuzono","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105332_bib0205","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","article-title":"Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: in vivo evaluation in rodents and Cynomolgus monkeys","volume":"58","author":"Martin","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105332_bib0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bmcl.2016.12.003","article-title":"Imidazopyridyl compounds as aldosterone synthase inhibitors","volume":"27","author":"Whitehead","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105332_bib0215","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bmcl.2017.12.015","article-title":"Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity","volume":"28","author":"Meyers","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105332_bib0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1074\/jbc.RA118.006214","article-title":"Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design","volume":"294","author":"Brixius-Anderko","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105332_bib0225","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/me.2012-1287","article-title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition","volume":"27","author":"Strushkevich","year":"2013","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2020.105332_bib0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature07614","article-title":"Structural basis for androgen specificity and oestrogen synthesis in human aromatase","volume":"457","author":"Ghosh","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.phrs.2020.105332_bib0235","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0240","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.phrs.2020.105332_bib0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"EMPHASIS-HF study group, eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2020.105332_bib0255","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105332_bib0260","series-title":"Angiotensin AT 1 Receptor Subtype As a Cardiac Target of Aldosterone Role in Aldosterone-salt-Induced Fibrosis","author":"Robert","year":"1999"},{"key":"10.1016\/j.phrs.2020.105332_bib0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvn064","article-title":"Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization","volume":"79","author":"Yamada","year":"2008","journal-title":"Cardiovasc. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:15:50Z","timestamp":1760912150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820316406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":53,"alternative-id":["S1043661820316406"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105332","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105332"}}